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Additionally, the high conversion
rate (two of five) in those who
reported consistent mask use when
caring for active TB cases may sug-
gest overreporting of mask use, poor
adjustment of the mask, contact with
unsuspected active cases (9), or con-
tact with a contaminated environment.
This high TST conversion rate and
incidence of TB demonstrate the inad-
equacy of hospital infection control
measures. In Peru, both unsuspected
active TB and multidrug-resistant TB
are highly prevalent (9). Rapid detec-
tion and respiratory isolation of
patients with active or suspected TB
are rarely practiced. 
In conclusion, Peruvian physicians
have an extremely high risk of TST
conversion and active TB. Hospitals in
developing countries need to design
and implement effective and appropri-
ate infection control measures such as
appropriate mask usage, sputum test-
ing, and rapid reporting of MTB
smears of all patients with respiratory
symptoms, as well as respiratory con-
trol for smear-positive TB cases (10).
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First Documented 
Human Rickettsia 
aeschlimannii 
Infection
To the Editor: Rickettsia aeschli-
mannii, which was first isolated from
Hyalomma marginatum ticks collected
in Morocco in 1997 (1), has also been
found in H. marginatum ticks from
Zimbabwe, Niger, and Mali (2). For
the past 3 years, we have included this
species in the panel of rickettsiae for
which sera from patients with sus-
pected tickborne diseases are routinely
tested. This procedure allowed us to
document, by polymerase chain reac-
tion (PCR) amplification and sero-
logic testing, the first case of R.
aeschlimannii human infection, which
occurred in a patient returning from
Morocco.
This 36-year-old man traveled to
Morocco in August 2000. On return-
ing to France, he noticed a vesicular
lesion of the ankle, which became
necrotic and resembled the typical
“tâche noire” of Mediterranean spot-
ted fever (3). He became ill with fever
of 39.5°C and a generalized maculo-
papular skin rash. Laboratory tests
showed a normal blood cell count but
moderately increased transaminases.
An early serum specimen was tested
to confirm the diagnosis of Mediterra-
nean spotted fever. By microimmuno-
fluorescence, the patient’s serum had
immunoglobulin G and M titers of
1:32 and 1:16, respectively, against R.
aeschlimannii; 0 and 1:16 against R.
conorii, R. africae, R. slovaca, R. hel-
vetica, and R. massiliae; and 0 and 1:8
against “R. mongolotimonae.” West-
ern blot results showed that the
patient’s serum reacted more inten-
sively with R. aeschlimannii proteins
than with those of the other tested
rickettsiae. Attempted PCR amplifica-
tion of a 630-nt portion of the rickett-
sial ompA gene (nt 70 to 701) (4) from
the early serum specimen yielded a
product of the expected size. The
sequence of this amplicon allowed the
identification of R. aeschlimannii with
100% homology. The patient was
treated with doxycycline, 200 mg
daily for 1 week, and rapidly recov-
ered.
This case is the first documented
infection caused by R. aeschlimannii,
a  Rickettsia that had been isolated
only from Hyalomma marginatum
ticks from Africa. In our patient, its
pathogenic role was demonstrated by
PCR, a technique that has also proven
useful in identifying other new rickett-
sial diseases, including infections withEmerging Infectious Diseases  •  Vol. 8, No. 7, July 2002 749
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R. helvetica (5), R. slovaca (6), and R.
felis (7). The serologic findings indi-
cated antibodies at a higher level to R.
aeschlimannii than to other tested spe-
cies. R. aeschlimannii is phylogeneti-
cally distant from R. conorii but is
closely related to R. rhipicephali and
R. montanensis, which have never
been described as human pathogens.
This patient appeared to have a typical
case of R. conorii infection, with sea-
sonal and geographic characteristics
favoring this diagnosis (3). This case
was clinically and epidemiologically
mistaken for R. conorii infection, sug-
gesting that R. aeschlimanii may be
another cause of Mediterranean spot-
ted fever in Morocco. 
The systematic identification of
rickettsial species in human infections
continues to increase the number of
recognized human pathogens (3). This
finding has demonstrated once again
that more than one species or serotype
of tick-transmitted rickettsia may be
prevalent in the same area, as
observed, for example, with R. slo-
vaca, “R. mongolotimonae,”  and  R.
conorii in southern France (3); R. afri-
cae and R. conorii in sub-Saharan
Africa (8); and R. conorii and Israeli
spotted fever rickettsia in Sicily and
Portugal (9). Rickettsia species first
identified in ticks should be consid-
ered as potential human pathogens, as
all recently described tick-transmitted
rickettsiae pathogenic for humans
were initially found in ticks and were
considered nonpathogenic for several
years (3).
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Cost-Effective 
Screening for 
Trichomoniasis
To the Editor:  I read with interest
a recent article in your journal,  “Tri-
chomonas vaginalis, HIV, and African
Americans” (1), and I commend the
authors’ suggestion to implement
screening and reporting of trichomoni-
asis for high-risk populations. 
In the article, a cost-effective
screening approach is mentioned,
which includes culturing only for
those women whose wet-mount tests
are negative. In 1999, my colleagues
and I reported on the validity of this
method for diagnosing trichomoniasis
in women (2). During our study, an
additional vaginal swab was collected
during the pelvic examination and
placed into a glass tube. If the wet
mount was negative, this swab was
later added to a culture pouch for T.
vaginalis. We found no statistically
significant difference in the sensitivity
of this method compared with that of
adding swabs immediately to pouches
at bedside. This method of delaying
the second test until the results of the
first test are known should be consid-
ered in screening women for tri-
chomoniasis, especially in high-
prevalence populations.
Jane R. Schwebke
University of Alabama at Birmingham, Bir-
mingham, Alabama, USA
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Reply to Dr. Schwebke
To the Editor:  We welcome Dr.
Schwebke’s thoughtful comments
about decreasing the cost of screening
for  Trichomonas vaginalis. Dr.
Schwebke and her colleagues have
demonstrated that storing a vaginal
swab for 15–20 minutes in a glass tube
at room temperature does not affect
the viability of T. vaginalis or reduce
the sensitivity of subsequent culture.
This finding shows that vaginal swabs
may be stored briefly while a wet-
mount preparation is made and exam-
ined. If the wet mount is negative for
T. vaginalis, the stored swab can then
be processed for culture. If the wet
mount is positive for T. vaginalis, no
further culture of the specimen is
needed, thereby reducing unnecessary
costs.  Given that the prevalence of
this infection often exceeds 20% in
high-risk populations, this approach
can reduce costs substantially without
compromising the accuracy of the
tests. Any method that reduces the
cost of diagnosis will advance further